# Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

> **Open Intelligence Dossier** · First detected: 2026-07-27 16:07 UTC · Category: Business

## Executive Summary
FDA scientists are disputing efficacy claims regarding Capricor Therapeutics' Phase 3 Duchenne muscular dystrophy cell therapy, triggering a stock plunge.

## Intelligence Brief
Food and Drug Administration (FDA) is formally questioning the efficacy of a cell therapy developed by Capricor Therapeutics intended to treat Duchenne muscular dystrophy (DMD). According to coverage from STAT and BioSpace, this scrutiny is occurring ahead of a scheduled hearing. The agency's staff has specifically disputed claims made by Capricor regarding the success of its Phase 3 clinical trials. These regulatory concerns have had an immediate impact on the company's financial standing, with Reuters reporting that Capricor shares plunged following the disclosure of the FDA staff's data concerns. Multiple industry and financial outlets are tracking the development. BioPharma Dive and BioSpace emphasize the conflict between the FDA's scientists and the data presented by Capricor.


Reuters focuses on the market reaction and the flagging of data concerns by agency staff. Additionally, Yahoo Finance has highlighted the broader investment narrative surrounding the company, noting how Capricor's manufacturing expansion and its FDA-linked headquarters have influenced its profile among investors. The consensus across these reports is a critical tension between the company's internal claims of success and the FDA's external validation process. To understand the current stakes, it is necessary to note that the therapy in question is a cell-based treatment targeting Duchenne muscular dystrophy, a severe genetic disorder. The progression of a drug from Phase 3 trials to regulatory approval is the final critical hurdle before a treatment can reach the general patient population. For Capricor, the validity of the Phase 3 data is the primary determinant of whether the therapy will be authorized for use.


The timing of these questions is particularly sensitive as they emerge just before a formal hearing designed to determine the drug's fate. Moving forward, the primary point of observation will be the upcoming hearing where the FDA's questions regarding efficacy and data concerns will be addressed. Market participants and stakeholders will be watching for the specific nature of the data discrepancies identified by FDA scientists. Coverage also indicates a broader shift in leadership within the biotech sector, as BioPharma Dive mentions that the CEO of Legend is stepping down, though the coverage does not specify a direct link between that departure and the Capricor regulatory challenges. The outcome of the FDA hearing will dictate whether Capricor's DMD therapy can move toward approval.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Moomoo | Roth Capital Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $7 From $38 | [Source Link](https://news.google.com/rss/articles/CBMitgFBVV95cUxNYXNWRGQ2ajI3TXB5QUVxT3FSc0tkcWNoU1FXb2l6Tlk0YmZhel9UNU5Db21hd3ZHZUZhZmtzdGFfV2liR2tjS1VyWU5QQk9iQVBBakpUSWZVTmdQNFZfOW5QaUhZNUx3ZmVGN2Z1clhTX2hieEptZ0NlVE9LZ3pnbWxQNFlMdk01Rk5Gc2VVSEdGenZmQ2pISTFZSWRDa0pZWEo5UmFLTXl1U3huN2NLZzRZcXI5QQ?oc=5) |
| Yahoo Finance | CAPR Stock Eyes Worst Month In 9 Years On FDA Doubts — ‘Pharma Bro’ Shkreli Piles On, But Retail Turns More Bullish Than Ever | [Source Link](https://news.google.com/rss/articles/CBMilwFBVV95cUxOeFBCbzR4Rmh3MHUySng3dEc5dWdUeEtSVldKMnQ4YXhsb3l1azI1LVN1VHhqNDVFai1pdmt1Yld2bk84WU5zcTZtVmliN2JMTmxKeVhJcXVCYlFERkY3Z2FocExTTmtPS19uVmNmblhVUFRTOEhEVndyWUs4bzFHV2RDZnZoR1E3Y25uTUFJUmNwYWF3UF9B?oc=5) |
| GlobeNewswire | Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel | [Source Link](https://news.google.com/rss/articles/CBMihAJBVV95cUxPMXowVHhiZmNMZGY0MTh1RG5LcDdYZGJtT0tING4taHFjMkliSVE1d0pVRzkyN3hUbV9kVFF2SWUyTE91UWJuaUY0WHF6V0VIYU1QMElQZVllQlFoY1hhQk1ES2JuSVBPSEpZTVc3QVk1WDRmTFBJbFZFOS1mSTNuY2NjSE0zVTlWMUJyU05ORk5aSHhMcV91VUVOaGgwX3M4Q1lKN0g5RnVLRVJrMnNXdTd4a0NGeV9PQVNMbW5PWW84bmpoZjdfMUxoYjhiTjFUbVF0Y3A0U3dac2JtWHhBaUZrcjdFZjJYeThDZXZsN0tEZXlNNzVua2FYS1pENHNTcWlCSQ?oc=5) |
| FirstWord Pharma | FDA staff report throws cold water on Capricor's DMD cell therapy bid | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE96Q2M0Q3ZkREljbllFY3RWeXhrTDJGRmQ0OVM2WmN5TTQ0aGswVUJadzBNZHNWSGRmX2U5dDFiTGJvTjBJdnVvUjFSTGQ4VXhYVDhV?oc=5) |
| BioWorld News | Adcom ‘cage match’ in store for Capricor? | [Source Link](https://news.google.com/rss/articles/CBMihgFBVV95cUxPb1EyZG5RTlJXTWtzNk9fUlljZDlCa012WU5vakNOQW1xZnl6U3RSeVlZLUZJd1JpV1RtV0REOC1MaGdkeDZCbzFTUkZoblVjQmNVYVFxOG9jLVlWVGpoNHZKYjRLc1FfaTdrajNLYjlSN1Vqd3QxUjNoZjNoVTMtemVWTXNqdw?oc=5) |
| Intellectia AI | Capricor Provides Update on Deramiocel for DMD Ahead of FDA Meeting | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxOVUxMODZkNDM4dC1TMU9UaF9jWjZ0ZXBzY3ZGTl9UVjUzLXRnRThqOHpIb2t5SU10TXJMUVliNV9lMjMtWkxBSm0xU2FzREZvXzBNSnB1Z3Z3WVRnMndUSkRibFJwLUJrdlZDWmFOYjdldVJJa0FJSzNrX2h5NG5oN0FSbUZXUWcwNjk3QmctbVFKeUtNT2J2bmZ4MlhheXNWYXNj?oc=5) |
| BioPharma Dive | FDA scientists question Capricor data; Legend CEO steps down | [Source Link](https://news.google.com/rss/articles/CBMimwFBVV95cUxOcTFaN09vdWxVaERiT2xDdV9jdEs3TWlqaUNfb0I3QXJ1NXU4RHZFNTFYdEF4SFZLXzRXMlNpTHpzQ3BtSUUtb01MU3dlTmozVm5uRzRFeGVLaHJ0dGY2aWExTmtYNnNzYVpkLU91djdkYk1iWDdYdDhYTlBoQXh4N3diU2Q0S3ZDSndEWk14ajE0Z1RzRnJQdkRlVQ?oc=5) |
| BioSpace | FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxNRkUzS1hSNTg1RC12NGxidVczTzVSVXo5ZjZ2RDVVTGtac2Fnb2R2UmRIX01ia0JRY3NwUW5keDZsSkJuZWdkQjlQbnlpMlNVbldIaWllTk5ibFlTUFpnLWFXTGM2UXRZaC1fWm13b2dOaHJ6SU5oUnhZN214MmxDMEY3UnRYMGVyVzlQdGlsajhVanE4VExPLVBrTzhmTFlRZkIwNWlHRlk2RVkwVGk3Yw?oc=5) |
| Reuters | FDA staff flags data concerns about Capricor's therapy; shares plunge | [Source Link](https://news.google.com/rss/articles/CBMi0wFBVV95cUxQVnBOS1RYdGpTaVNfVHVYVExxdTl4OGtNX3ZUYTNTYmZjRmdTeEpsdlM5cUhkNW94OE1najhrVEhMVFUyenBJb0ptMElPNG9GcTc3NDJueGEyOG5MS3ZWeFlzdWhvbFRIdlNNWkRWV1VxTGlzX2Y3VGhJcmFMVjNQT0VETFRWekpiSkN0NTY3UkNEcXp1dmd6ZEZYSGhmdE9oXzdOYmh4NEZuYklGUjBBRTM4SVRvOVNxTzNQZUVYLXllRkQtUW1WSm1kcGtJaHF3cHBF?oc=5) |
| Yahoo Finance | How FDA‑Linked HQ and Manufacturing Expansion At Capricor Therapeutics (CAPR) Has Changed Its Investment Story | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxQTk91U3lkaFBxZWlLN3VFYUJnTzJscjhTbC0yNEs4SDhwVG40V3dvYmpJdHhIUTliNjBzOUtHTnByWkpINXItRmZCY3VYOHRScENjZXQ2N2RwcmY1aWp5eUlFeTJmWVU0eURQYURvWnh4aUVMTk1iT3QwMjN1N1FLYjVMTlF2cmF5YUdMMVZ5XzFob191YmlYXzJhdmZiVDA?oc=5) |
| STAT | Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTWt4LUgxVEFrN0dBV0RCa0drek85eWJJSlozMHBJamRuVVd1b2RCS1g5OVlDcThhRFd4U2dNNmFtdDQzcWJVdnN6OVhEVURSUmtHNnRLNFlqMFFPM2FkNXhIYjFRX2F3U2xkR0lETUdoOV8tQzdNVjFpU21XTHlmS0xic216ckJsdnU3RDhCbjBzVUVqSUhSRlU2emtfZ0pXRFpJTDZ6Zlh6UQ?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-07-27/ahead-of-hearing-fda-questions-the-efficacy-of-capricor-s-duchenne-drug*